EGLT News Alert Egalet Corp (EGLT) 6.26 12/12/2014 23:06:03

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 12:06 AM

Egalet Corp (EGLT) 6.26 $EGLT

The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities 2014-19: Egalet 002 to Take Over from Oxycontin and Oxycodone
M2 - Mon Dec 08, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/t568bs/the_us_chronic) has announced the addition of the "The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-19)" report to their offering. The report titled The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019) provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating. The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market. Company Coverage - Zogenix Inc. - Egalet Corporation - NektarTheropeutics Key Topics Covered: 1. Executive summary 2. Introduction: Chronic Pain 3. The US Chronic Pain Therapy Market 4. The US Chronic Pain Therapy Market: Segment Analysis 5. The US Chronic Pain Therapy: Market Share Analysis 6. Growth Drivers and Challenges:The US Chronic Pain Therapy Market 8. Competitive Landscape:The US Chronic Pain Therapy Market 9. Company Profiles:The US Chronic Pain Therapy Market For more information visit http://www.researchandmarkets.com/research/t5...us_chronic
EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02)

Nasdaq stocks posting largest percentage increases
AP - Fri Dec 05, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RESN: 9.01 (-0.10), BIRT: 6.54 (-0.01), EGLT: 6.26 (+0.19), ARWR: 5.76 (-0.17), SIMG: 6.76 (-0.10)

United States Chronic Pain Industry 2014 Trends and 2019 Opportunities Now Available at MarketReportsOnline.com
PRWeb - Tue Dec 02, 2:55AM CST
The report titled "The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)" provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.
EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02)

FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 12:36PM CST

MNK: 94.72 (-0.36), EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02), PFE: 30.95 (-0.70), TEVA: 55.92 (-0.92), ABBV: 65.27 (-1.76), ALKS: 54.41 (-1.22), ACUR: 0.47 (-0.05)

Egalet's (EGLT) CEO Bob Radie on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 11:18AM CST

EGLT: 6.26 (+0.19)

Egalet net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:29AM CST

EGLT: 6.26 (+0.19)

Egalet beats by $0.14
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 5:41AM CST

EGLT: 6.26 (+0.19)

Egalet Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Wed Nov 12, 5:00AM CST
Egalet Corporation (Nasdaq: EGLT) ("Egalet"

today reported business highlights and financial results for the three months ended September 30, 2014.
EGLT: 6.26 (+0.19)

Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 13.82 (-0.86), PFE: 30.95 (-0.70), AMGN: 164.53 (-1.55), AXN: 0.30 (unch), SRNE: 5.80 (+0.37), NKTR: 15.31 (-0.29), EGLT: 6.26 (+0.19), AZN: 71.80 (-1.80), VBAY: ()

Egalet to Present at the Stifel 2014 Healthcare Conference on November 18
GlobeNewswire - Wed Nov 05, 7:30AM CST
Egalet Corporation (Nasdaq:EGLT) ("Egalet"

today announced that Bob Radie, president and chief executive officer, is scheduled to present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 4:10 p.m. EST. The conference will be held at the New York Palace Hotel.
EGLT: 6.26 (+0.19)

Egalet to Host Conference Call and Webcast to Discuss Third Quarter Financial Results on November 12, 2014
PR Newswire - Wed Oct 29, 7:30AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"

today announced that its third quarter financial results will be released on Wednesday, November 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update.
EGLT: 6.26 (+0.19)

FDA clears Pfizer's abuse deterrent pain med
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 4:20PM CDT

MNK: 94.72 (-0.36), EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02), PFE: 30.95 (-0.70), TEVA: 55.92 (-0.92), ABBV: 65.27 (-1.76), ALKS: 54.41 (-1.22), ACUR: 0.47 (-0.05)

2 Oversold Stocks Under $10 Ready to Bounce Higher
at The Street - Fri Oct 17, 8:05AM CDT
Oversold can always get more oversold, but it's also an area from which a stock can experience a powerful bounce higher.
AMKR: 6.31 (-0.14), EGLT: 6.26 (+0.19)

Egalet (EGLT) Shows Strength: Stock Moves 7.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 8:46AM CDT
Egalet (EGLT) was a big mover last session, with shares rising over 7% on the day.
LCI: 43.58 (-0.46), EGLT: 6.26 (+0.19), SHPG: 213.70 (-0.41), CEMP: 19.00 (+0.47)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Air Sealing First: Boosting Home Comfort & Efficiency

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...